ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå : µ¥ÀÌÅÍ À¯Çüº°, µµÀÔ ¸ðµåº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
De-identified Health Data Market, By Data Type, By Deployment Mode, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1574986
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 260 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,612,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,598,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,017,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 75¾ï 4,909¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â CAGR 9.20%·Î È®´ë

ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - ½ÃÀå ¿ªÇÐ

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÇ Áõ°¡°¡ ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀÇ ¼ö¿ä¸¦ ÃËÁø

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ȯÀÚ µ¥ÀÌÅ͸¦ Ȱ¿ëÇÏ¿© Ä¡·á¸¦ ¸ÂÃãÈ­Çϱâ À§ÇØ È¯ÀÚ µ¥ÀÌÅ͸¦ »ç¿ëÇÏ´Â °æ¿ì°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ º¸°Çº¹ÁöºÎ º¸°í¼­¿¡ µû¸£¸é ¸ÂÃãÇü ÀÇ·á´Â ȯÀÚ °á°ú °³¼±°ú ÀÇ·áºñ Àý°¨À¸·Î À̾îÁø´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ All of Us ¿¬±¸ ÇÁ·Î±×·¥°ú °°Àº ±¸»óÀº °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» °­È­Çϱâ À§ÇØ ´Ù¾çÇÑ Áý´ÜÀ¸·ÎºÎÅÍ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, IBM°ú Google°ú °°Àº ÁÖ¿ä ÇÏÀÌÅ×Å© ±â¾÷Àº AI ¹× ºÐ¼® Åø¿¡ ÅõÀÚÇÏ¿© ¿¬±¸ ¹× ÀÓ»ó ÀÀ¿ëÀ» À§ÇØ ºñ½Äº°È­µÈ °Ç°­ µ¥ÀÌÅ͸¦ Ȱ¿ëÇÏ¿© °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ Áøº¸¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå Ãß¼¼´Â ȯÀÚÀÇ ÇÁ¶óÀ̹ö½Ã¸¦ À¯ÁöÇϸ鼭 ÀÇ·á ¼­ºñ½º¸¦ °³¼±ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¾ÈÀüÇϰí ÄÄÇöóÀ̾𽺸¦ ÁؼöÇÏ´Â µ¥ÀÌÅÍ Ãë±ÞÀÌ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ½À» °­Á¶ÇÕ´Ï´Ù.

ºñ½Äº°È­µÈ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¸Å³â ¾à 9.20%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µ¥ÀÌÅÍ À¯Çüº°·Î´Â ÀüÀڰǰ­±â·ÏÀÌ 22023³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¹èÄ¡ ¸ðµåº°·Î´Â Ŭ¶ó¿ìµå ±â¹ÝÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ²ÅÇû½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â¿¡ ¸ÅÃâÀ» âÃâÇÒ ÁÖ¿ä ½ÃÀåÀÔ´Ï´Ù.

ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀº µ¥ÀÌÅÍ À¯Çü, ¹èÆ÷ ¸ðµå, ¾ÖÇø®ÄÉÀÌ¼Ç ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

ÀüÀÚÀǹ«±â·Ï(EHR)Àº Á¾ÇÕÀûÀΠȯÀÚ Á¤º¸¸¦ Á¦°øÇϹǷΠ°¡Àå ¿ì¼±¼øÀ§°¡ ³ô½À´Ï´Ù. ±× ´ÙÀ½À¸·Î´Â ÀÇ·á ºñ¿ë¿¡ ´ëÇÑ ÀλçÀÌÆ®À» Á¦°øÇÏ´Â ÇコÄÉ¾î µ¥ÀÌÅÍ(Claims Data), ÀÓ»ó µ¥ÀÌÅÍ(Clinical Data), Àü¹®Àû ÀλçÀÌÆ®À» Á¦°øÇÏ´Â À¯Àüü µ¥ÀÌÅÍ(Genomic Data)°¡ ±× µÚ¸¦ ÀÕ½À´Ï´Ù.

½ÃÀåÀº ±¸Ãà ¹æ½Ä¿¡ µû¶ó ¿ÂÇÁ·¹¹Ì½ºÇü°ú Ŭ¶ó¿ìµå ±â¹ÝÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ±¸ÃàÀÌ ¼±È£µÇ´Â ÀÌÀ¯´Â È®À强°ú ºñ¿ë È¿À²¼º, ±×¸®°í µ¥ÀÌÅÍ¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿ÂÇÁ·¹¹Ì½º ¼Ö·ç¼ÇÀº ´õ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇÏÁö¸¸ ±â¹Ð ÀÇ·á Á¤º¸ÀÇ º¸¾È°ú °ü¸®°¡ °­È­µÈ´Ù´Â Á¡¿¡¼­ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

ºñ½Äº°È­µÈ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

ºÏ¹Ì¿¡¼­ ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀº ¼ö¸¹Àº ÇコÄÉ¾î µ¥ÀÌÅÍ ±â¾÷°ú °í±Þ ºÐ¼® ±â¾÷ÀÇ º»°ÅÁöÀÎ ¹Ì±¹ÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº 2022³â ¾à 220¾ï ´Þ·¯ÀÇ °Ç°­ µ¥ÀÌÅÍ ¼öÀÔÀ» ¿¹»óÇϰí ÀÖÀ¸¸ç, µ¥ÀÌÅͺ£À̽º ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ¸¹Àº ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â EUÀÇ ÀÏ¹Ý µ¥ÀÌÅÍ º¸È£ ±ÔÁ¤(GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤))ÀÌ ºñ½Äº°È­µÈ µ¥ÀÌÅÍÀÇ Ã¥ÀÓ°¨ ÀÖ´Â »ç¿ëÀ» Àå·ÁÇϸ鼭 ½ÃÀåÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, µ¶Àϰú ¿µ±¹°ú °°Àº ±¹°¡µéÀÌ ÇコÄÉ¾î ºÐ¼® ¿ª·®À» È®´ëÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÇÑÆí, Àεµ¿Í Áß±¹ µî ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àεµ¿Í Áß±¹ µîÀÇ ±¹°¡µéÀÌ µðÁöÅÐ Çコ ºÐ¾ß¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, À¯·ÂÇÑ È帷Π¶°¿À¸£°í ÀÖ½À´Ï´Ù. ÀεµÀÇ ÇコÄɾî IT ºÎ¹®Àº 2025³â±îÁö 90¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ºñ½Äº°È­µÈ °Ç°­ µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«µµ °Ç°­ µ¥ÀÌÅÍÀÇ Á߿伺À» ÀνÄÇϰí ÀÖÀ¸¸ç, ºê¶óÁúÀº °øÁߺ¸°Ç Çâ»óÀ» À§ÇÑ ºñ½Äº°È­ µ¥ÀÌÅÍ È°¿ëÀ» ÃËÁøÇÏ´Â °Ç°­ µ¥ÀÌÅ͹ýÀ» µµÀÔÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀû ³ë·ÂÀÌ ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍÀÇ ¼¼°è »óȲÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù.

ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - °æÀï ȯ°æ:

ºÏ¹Ì´Â ±â¼ú ¹ßÀü°ú źźÇÑ ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ ÈûÀÔ¾î ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå¿¡¼­ ¿©ÀüÈ÷ ÁÖ¿ä Áö¿ªÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, 2023³â 1¿ù ÇコÄÉ¾î ¼­ºñ½º ±â¾÷ ¿ÉÅÒ(Optum)Àº ÀÇ·á Á¦°øÀÚ¿¡ °í±Þ ÀλçÀÌÆ®¸¦ Á¦°øÇϱâ À§ÇØ ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ Á¦°øÀ» °­È­Çϱâ À§ÇÑ Àü·«Àû Á¦ÈÞ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ±â¾÷ ¿ÉÅÒ(Optum)Àº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô °í±Þ ÀλçÀÌÆ®¸¦ Á¦°øÇϱâ À§ÇØ ÁÖ¿ä ºÐ¼® ±â¾÷°úÀÇ Àü·«Àû Á¦ÈÞ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÇÑÆí, À¯·´¿¡¼­´Â 2023³â 3¿ù Áö¸à½º Çï½Ã´Ï¾î½º(Siemens Healthineers)¿Í À¯·´ ºÐ¼® ±â¾÷ °£ ºñ½Äº°È­µÈ ȯÀÚ µ¥ÀÌÅ͸¦ ¿¬±¸ ¸ñÀûÀ¸·Î Ȱ¿ëÇϰí ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇÑ Áß¿äÇÑ ÆÄÆ®³Ê½ÊÀÌ Ã¼°áµÇ¾ú½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â 2022³â ÇϹݱâ À¯¸í ÇコÄÉ¾î ½ºÅ¸Æ®¾÷ÀÌ ÇöÁö µ¥ÀÌÅÍ ºÐ¼® ¾÷ü¸¦ ÀμöÇÏ¿© ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ °ü¸® ¿ª·®À» È®´ëÇß½À´Ï´Ù. ¶ÇÇÑ ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀÇ ¼ºÀåÀº ¹Ì±¹ ÀÇ·áÁ¤º¸±â¼ú Á¶Á¤°ü½ÇÀÇ °Ç°­ µ¥ÀÌÅÍÀÇ Ã¥ÀÓ°¨ ÀÖ´Â »ç¿ëÀ» Àå·ÁÇÏ´Â µî À¯¸®ÇÑ ±ÔÁ¦¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿òÁ÷ÀÓÀº Àü ¼¼°è¿¡¼­ Çõ½Å°ú Çù¾÷ÀÌ °­Á¶µÇ°í ÀÖ´Â °æÀï ȯ°æÀÇ ¿ªµ¿ÀûÀΠƯ¼ºÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ »ê¾÷ÀÇ Á¶»ç

Á¦5Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå ±¸µµ

Á¦7Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - µ¥ÀÌÅÍ À¯Çüº°

Á¦8Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - µµÀÔ ¸ðµåº°

Á¦9Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - ¿ëµµº°

Á¦10Àå ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ºñ½Äº°È­ °Ç°­ µ¥ÀÌÅÍ ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

De-identified Health Data Market size was valued at USD 7,549.09 Million in 2023, expanding at a CAGR of 9.20% from 2024 to 2032.

The de-identified health data market involves the collection, analysis, and sale of health data that has been stripped of personally identifiable information, ensuring patient confidentiality. As healthcare organizations increasingly seek insights from big data analytics to improve patient outcomes and operational efficiency, the demand for de-identified data is surging. Factors contributing to this growth include the rising emphasis on personalized medicine, which necessitates large datasets for effective analysis. Furthermore, initiatives promoting interoperability among health systems facilitate data sharing, enhancing the accessibility of de-identified health data. However, challenges such as data security concerns and regulatory compliance issues may hinder market growth. Opportunities exist in the expansion of artificial intelligence and machine learning technologies, which require extensive datasets for training algorithms. For instance, studies indicate that over 80% of healthcare providers plan to invest in analytics solutions by 2025, underscoring the increasing reliance on de-identified health data to drive innovation and improve healthcare delivery.

De-identified Health Data Market- Market Dynamics

Growing Focus on Personalized Medicine Drives Demand in the De-identified Health Data Market

The rising focus on personalized medicine is significantly propelling demand in the De-identified Health Data Market. As healthcare providers increasingly utilize patient data to tailor treatments, the need for de-identified health data has surged. According to a report from the U.S. Department of Health & Human Services, personalized medicine can lead to better patient outcomes and reduced healthcare costs. Additionally, initiatives like the All of Us Research Program aim to gather data from diverse populations to enhance individualized treatment approaches. Major tech firms, including IBM and Google, are investing in AI and analytics tools to leverage de-identified health data for research and clinical applications, facilitating advancements in personalized therapies. This growing trend highlights the critical role of secure and compliant data handling in improving healthcare services while maintaining patient privacy.

De-identified Health Data Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.20% over the forecast period (2024-2032)

Based on Data Type segmentation, Electronic Health Records was predicted to show maximum market share in the year 2023

Based on Deployment Mode segmentation, Cloud-Based was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

De-identified Health Data Market- Segmentation Analysis:

The Global De-identified Health Data Market is segmented on the basis of Data Type, Deployment Mode, Application, and Region.

The market is divided into four categories based on data type: electronic health records (EHR) are the highest priority due to their comprehensive patient information. Following closely are Claims Data, which provides insights into healthcare costs, Clinical Data, and Genomic Data, which offers specialized insights.

The market is divided into two categories based on Deployment Mode: On-Premise and Cloud-Based. Cloud-based deployment is prioritized due to its scalability and cost-effectiveness, allowing easier access to data. On-premise solutions follow, favored for enhanced security and control over sensitive health information, though they require more investment.

De-identified Health Data Market- Geographical Insights

In North America, the De-identified Health Data Market is led by the United States, which is home to numerous healthcare data companies and advanced analytics firms. The U.S. generated approximately $22 billion in health data revenue in 2022, showcasing the significant investment in data-driven healthcare solutions. In Europe, the market is growing due to the European Union's General Data Protection Regulation (GDPR), which encourages the responsible use of de-identified data, allowing countries like Germany and the UK to expand their healthcare analytics capabilities. Meanwhile, the Asia Pacific region is emerging as a strong contender, with countries like India and China focusing on digital health initiatives. India's healthcare IT sector is projected to grow to $9 billion by 2025, indicating a rising demand for de-identified health data. Latin America is also recognizing the importance of health data, with Brazil implementing health data laws that facilitate de-identified data use for public health improvements. These regional initiatives are reshaping the de-identified health data landscape globally.

De-identified Health Data Market- Competitive Landscape:

In the De-identified Health Data Market, North America remains the leading region, driven by technological advancements and robust healthcare systems. In January 2023, Optum, a health services company, announced a strategic partnership with a leading analytics firm to enhance its de-identified health data offerings, aiming to provide advanced insights to healthcare providers. Meanwhile, in Europe, a significant collaboration occurred in March 2023 between Siemens Healthineers and a European analytics company to leverage de-identified patient data for research purposes, enhancing patient outcomes. In the Asia Pacific, a notable merger took place in late 2022 when a prominent health tech startup acquired a local data analytics firm, expanding its capabilities in de-identified health data management. Additionally, the growth of the de-identified health data market is supported by favorable regulations, with the U.S. Office of the National Coordinator for Health Information Technology promoting the responsible use of health data. These developments reflect the competitive landscape's dynamic nature, emphasizing innovation and collaboration across the globe.

Recent Developments:

In February 2023, Mayo Clinic Platform and TripleBlind expanded their partnership to enhance de-identified data usage and patient privacy. This collaboration aims to improve global health outcomes by enabling secure data analysis without compromising patient information or intellectual property rights.

In April 2023, Philips and MIT's IMES enhanced the eICU Collaborative Research Database, providing researchers access to de-identified data from over 200,000 critical care patients. This initiative aims to advance AI in healthcare and improve clinical understanding and patient outcomes.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DE-IDENTIFIED HEALTH DATA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL DE-IDENTIFIED HEALTH DATA MARKET, BY DATA TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL DE-IDENTIFIED HEALTH DATA MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

GLOBAL DE-IDENTIFIED HEALTH DATA MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL DE-IDENTIFIED HEALTH DATA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. De-identified Health Data Market Overview

2. Executive Summary

3. De-identified Health Data Key Market Trends

4. De-identified Health Data Industry Study

5. De-identified Health Data Market: COVID-19 Impact Analysis

6. De-identified Health Data Market Landscape

7. De-identified Health Data Market - By Data Type

8. De-identified Health Data Market - By Deployment Mode

9. De-identified Health Data Market - By Application

10. De-identified Health Data Market- By Geography

11. Key Vendor Analysis- De-identified Health Data Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â